Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Bioluminescent Metabolite Assays Enable Easy Measurement of Changes in Tumor Biology

Part # PS301


Michael P. Valley, Donna Leippe, Mary Sobol, Natasha Karassina, Sarah Duellman, James J. Cali, and Jolanta Vidugiriene
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Abstract # 4026
Tumor cells rely on metabolic reprogramming to meet their increased demands for energy and biomass. Such reprogramming is exemplified by increased rates of glucose uptake, greater utilization of glycolysis, and a reliance on glutaminolysis. We have developed a suite of bioluminescent assays that can monitor metabolites in all of these important pathways.

Printed in USA.